Antibody News

The “Promising Novel Antitumor Strategies in Early Phase Clinical Trials” session at AACR2023 highlighted progress in evaluating new immunotherapy strategies targeting solid tumor antigens.

A recent study by investigators at the Center of Excellence in Systems Biology, Chulalongkorn University, Thailand, leveraged hybridoma technology and duplex high-throughput screening to identify new anti-PD-1 monoclonal antibodies checkpoint blockers.

Learn how gene to antibody services, including GenSciprt’s gene synthesis, codon-optimization, plasmid cloning, and plasmid preparation, support and expedite the discovery of antibody drugs.

Learn about antibody therapies undergoing FDA review during the first part of 2022 and those antibody drugs, including bispecific antibodies, at the very late stages of clinical evaluation.

Find out how iPSC-derived cerebral organoids enable the screening of FDA approved drugs to reduce pathogenic protein aggregates in association with Alzheimer’s disease.

Learn how IL3 and IL3 receptor alpha based communication between astrocytes and microglia represents a potential therapeutic target in Alzheimer’s disease

Learn about the less well-known post-translational modification AMPylation, newly developed tools to identify AMP-modified proteins, and recently identified AMPylated proteins in the brain.

Learn about the advantages and challenges of antibody-drug conjugates (ADC) as chemotherapeutics for various cancers.

The animal reservoir from SARS-CoV-2

Learn how anti-HIV vaccines are advancing towards the clinic and how investigators are devising vaccine strategies to promote anti-HIV neutralizing and non-neutralizing antibodies.